NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANT (NOAC) USE AND DOSING IN CANADIAN PRACTICE: INSIGHTS FROM THE OPTIMIZING PHARMACOTHERAPY IN THE MANAGEMENT APPROACH TO LOWERING RISK IN ATRIAL FIBRILLATION (OPTIMAL-AF) PROGRAM